<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114707</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-040-01</org_study_id>
    <nct_id>NCT05114707</nct_id>
  </id_info>
  <brief_title>Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses</brief_title>
  <official_title>Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses: a Phase II Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for&#xD;
      this study. All the eligible patients receive three cycles of induction chemotherapy&#xD;
      (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two&#xD;
      cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides,&#xD;
      camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the&#xD;
      first day of induction chemotherapy. We aim to evaluate the three years failure free survival&#xD;
      of these patients by the combination of camrelizumab with curative radiotherapy and&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">April 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year failure free survival</measure>
    <time_frame>3-year</time_frame>
    <description>time from the randomization to the first treatment failure or death</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Nasal Cavity Cancer</condition>
  <condition>Paranasal Sinus Cancer</condition>
  <condition>Camrelizumab</condition>
  <condition>Induction Chemotherapy</condition>
  <condition>Intensity Modulated Radiotherapy</condition>
  <condition>Concurrent Chemotherapy</condition>
  <arm_group>
    <arm_group_label>camrelizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab</intervention_name>
    <description>Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.</description>
    <arm_group_label>camrelizumab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed squamous cancer of nasal cavity and paranasal sinuses&#xD;
&#xD;
          -  T4bN0-3M0 (AJCC8th) or unresectable lymph nodes or refusal of surgery&#xD;
&#xD;
          -  KPS≥70&#xD;
&#xD;
          -  NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L&#xD;
&#xD;
          -  ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN&#xD;
&#xD;
          -  creatinine clearance rate ≥ 60 ml/min (calculated by Cockcroft-Gault)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  older than 65 or younger than 18&#xD;
&#xD;
          -  HBsAg (+) and HBV DNA &gt;1×10E3 copiers /mL&#xD;
&#xD;
          -  HCV (+)&#xD;
&#xD;
          -  HIV (+)&#xD;
&#xD;
          -  autoimmune diseases&#xD;
&#xD;
          -  interstitial lung diseases&#xD;
&#xD;
          -  had other cancers before&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fei Han</last_name>
    <phone>+86 13822113698</phone>
    <email>hanfei@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pu-Yun OuYang</last_name>
    <phone>+86 18565382769</phone>
    <email>ouyangpy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Han, M.D.</last_name>
      <phone>+86 13822113698</phone>
      <email>hanfei@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Pu-Yun OuYang, M.D.</last_name>
      <phone>+86 18565382769</phone>
      <email>ouyangpy@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fei Han</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

